.png)
Pan-Tumor Assay to detect all types of hematologic malignancies throughout DNA & RNA next generation sequencing (NGS). It provides highly informative data that can be used for diagnosis, evaluation of the host immune response, and identification of biomarkers useful for predicting response to various therapies.
This test can significantly reduce the need for bone marrow biopsies for hematology patients. Furthermore,the test can detect chromosomal abnormalities, translocations, and geneamplifications.
All types of hematologic cancers are detected:
RNA sequencing has numerous benefits: ability to detect mutations that modify RNA expression levels, such as alternative splicing, stability, and allele-specific methylation.Additionally, there is an increase in sensitivity due to numerous copies of RNA against one copy of mutated DNA.This strategy, for example, benefits the detection of T-cell and B-cell clonality, HLA class I genotyping and Torque Teno virus (TTV) as a marker of the level of immune competence.
Sensitivity is 0.1 to 0.01 for non-hot spot, 0.01 to 0.001 for hotspot and <0.001 for tumor informed or prior Hx.
For DNA, QNS is rare (<0.1%),but it is higher for RNA (Good DNA results but poor RNA results. Of course, if we receive 3 ml of plasma (6 ml blood), the sample is QNS for performing RNA testing.
VAF (Variant Allele Frequency)value: This value is used to monitor the disease in liquid bx. The higher the VAF means higher tumor load. Patients showing reduction in VAF after treatment means they are doing better.
Peripheral blood (10 mL) in a Lavender-top(EDTA) tube.
Important: RNA stability is 48-72 hours from blood draw. DNA stability is 7 days from blood draw.Samples received beyond 72 hours may include only DNA results.
CSF (7-10 mL) is optimal (5 mL minimum).
Important: Ship as soon as possible (overnight). Do not use collection devices with anti-coagulants. Clear tubes.
Use cold pack for transport. Make sure cold pack is not in direct contact with specimen.